JPWO2020014591A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020014591A5
JPWO2020014591A5 JP2021500920A JP2021500920A JPWO2020014591A5 JP WO2020014591 A5 JPWO2020014591 A5 JP WO2020014591A5 JP 2021500920 A JP2021500920 A JP 2021500920A JP 2021500920 A JP2021500920 A JP 2021500920A JP WO2020014591 A5 JPWO2020014591 A5 JP WO2020014591A5
Authority
JP
Japan
Prior art keywords
apmv
nucleotide sequence
sequence encoding
recombinant
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021500920A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021530501A (ja
JP2021530501A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/041568 external-priority patent/WO2020014591A1/en
Publication of JP2021530501A publication Critical patent/JP2021530501A/ja
Publication of JPWO2020014591A5 publication Critical patent/JPWO2020014591A5/ja
Publication of JP2021530501A5 publication Critical patent/JP2021530501A5/ja
Pending legal-status Critical Current

Links

JP2021500920A 2018-07-13 2019-07-12 癌の治療のためのａｐｍｖ及びその使用 Pending JP2021530501A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862697944P 2018-07-13 2018-07-13
US62/697,944 2018-07-13
PCT/US2019/041568 WO2020014591A1 (en) 2018-07-13 2019-07-12 Apmv and uses thereof for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2021530501A JP2021530501A (ja) 2021-11-11
JPWO2020014591A5 true JPWO2020014591A5 (https=) 2022-07-26
JP2021530501A5 JP2021530501A5 (https=) 2022-07-26

Family

ID=69141914

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021500920A Pending JP2021530501A (ja) 2018-07-13 2019-07-12 癌の治療のためのａｐｍｖ及びその使用

Country Status (6)

Country Link
US (2) US20200297787A1 (https=)
EP (1) EP3820492A4 (https=)
JP (1) JP2021530501A (https=)
CN (1) CN112739359A (https=)
CA (1) CA3106170A1 (https=)
WO (1) WO2020014591A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
WO2021174121A1 (en) * 2020-02-27 2021-09-02 Icahn School Of Medicine At Mount Sinai Vegfr-3-activating agents and oncolytic viruses and uses thereof for the treatment of cancer
WO2022067038A1 (en) * 2020-09-25 2022-03-31 President And Fellows Of Harvard College Immunotherapeutic virus for the treatment of cancer
US20240199705A1 (en) * 2021-04-26 2024-06-20 Icahn School Of Medicine At Mount Sinai Chimeric newcastle disease virus expressing apmv hn and f proteins
CN117925916A (zh) * 2024-03-11 2024-04-26 广州市金域转化医学研究院有限公司 Hpv dna的e6基因在制备浸润性宫颈癌诊断产品中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0974660A1 (en) * 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
BRPI0517834A (pt) * 2004-11-12 2008-10-21 Bayer Schering Pharma Ag vìrus da doença de newcastle recombinante
US20090208495A1 (en) * 2008-02-14 2009-08-20 Bayer Schering Pharma Ag Anti-tumor effective paramyxovirus
HUE053237T2 (hu) * 2009-08-21 2021-06-28 Boehringer Ingelheim Animal Health Usa Inc Rekombináns madárparamixovírus-vakcina és eljárás elõállítására és alkalmazására
EP2579884B1 (en) * 2010-06-10 2014-06-04 Intervet International B.V. Anti-tumor composition
EA038981B1 (ru) * 2013-03-14 2021-11-17 Икан Скул Оф Медсин Эт Маунт Синай Вирусы болезни ньюкасла и их применение
WO2015032755A1 (en) * 2013-09-03 2015-03-12 Medimmune Limited Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia

Similar Documents

Publication Publication Date Title
JP2021530501A5 (https=)
JP6688535B2 (ja) ワクチン組成物
bin Umair et al. Viruses as tools in gene therapy, vaccine development, and cancer treatment: M. bin Umair et al.
Lundstrom Self-replicating RNA viruses for RNA therapeutics
US10925946B2 (en) Vaccination methods
Collins et al. Viral vectors in cancer immunotherapy: which vector for which strategy?
CN109310746B (zh) 过继细胞转移与溶瘤病毒组合疗法
US20190151437A1 (en) Combination prime: boost therapy
JP2016513115A5 (https=)
WO2014063601A1 (zh) 诱导肿瘤特异性免疫的疫苗及其应用
CN105031630A (zh) 同时分泌pd-1中和抗体和gm-csf因子的肿瘤细胞疫苗及其制备方法
JPWO2020014591A5 (https=)
Zinovieva et al. Oncolytic vesicular stomatitis virus: optimisation strategies for Anti-Cancer therapies
CN119736337A (zh) Matv51重组腺病毒载体、应用、制备方法及hpv16/18/52治疗性疫苗
TWI259206B (en) A DNA vaccine containing a tumor associated gene and a cytokine gene and the method producing thereof
CN120966775B (zh) 一种携带马尔堡病毒缺陷型g蛋白的无神经毒性vsv载体重组溶瘤病毒
CN120966774B (zh) 一种携带辛德毕斯病毒g蛋白的无神经毒性vsv载体重组溶瘤病毒
WO2024198943A1 (en) Homologous and heterologous therapeutic vaccination strategies for cancer treatment
Buchatskyi et al. Vesiculoviruses as a tool of biotechnology
Deepthi Growing promise of oncolytic virotherapy: opportunities and pitfalls of NDV in cancer therapy
Lundstrom Next-Generation Immunotherapies and Vaccines
HK40097194A (en) Adoptive cell transfer and oncolytic virus combination therapy
Singh et al. 458. Efficient Transduction of Human and Murine Cells and Circumvention of Preexisting Human Adenoviral Immunity by Porcine Adenoviral Vectors
Barcia et al. 459. Immune System Regulation of Transgene Expression in the Brain 1: Systemically Activated Immune Responses Silence Adenoviral Vector-Encoded Transgene Expression in the Brain Through Both Non-Cytolytic, and Cytotoxic Mechanisms
by Porcine CONDITIONALLY REPLICATING ADENOVIRUS VECTORS; ADENOVIRUS TOXICITY AND IMMUNE RESPONSE